A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Protocol: Alliance – A031702 SCHEMA A031702 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810)762-8038. Thank you! Eligibility: Metastatic disease defined as new or progressive lesions on cross-sectional imaging or bone scan. Patients must have at least:  a.One measurable site of disease […]